Protein-bound paclitaxel was developed by VivoRx which became Abraxis BioScience as the first in its class of drugs to use the nanoparticle albumin bound (nab) technology platform.
In 2010, Abraxis was acquired by Celgene, which now markets Abraxane.[12] Total revenue from the sales of Abraxane for 2009 were $314.5 million.[13] In 2013, Abraxane was FDA approved for the treatment of pancreatic cancer.
In 2014, Abraxane’s sales were $848 million, 31 percent year-over-year increase.
The British National Institute for Health and Care Excellence (NICE) announced in 2015 that it would not support the routine use of protein-bound paclitaxel in advanced pancreatic cancer on the NHS.
Abraxane is registered on the Australian Register of Therapeutic Goods for the treatment of metastatic carcinoma of the breast after failure of anthracycline therapy.
Abraxane is also included on the Schedule of the Australian Pharmaceutical Benefits Scheme although the manufacturer was unable to convince the independent Pharmaceutical Benefits Advisory Committee that the drug warranted a higher price than existing comparator drugs.
You must be logged in to post a review.
Reviews
There are no reviews yet.